P2RY12 and diabetes mellitus: Patients with early ezetimibe use were younger, more frequently revascularized, had more commonly diabetes, hypertension, or established vascular disease, and used ACEi/ARBs, beta-blockers, or P2Y12 inhibitors more commonly than patients without ezetimibe (Table 1).